{
    "name": "migalastat",
    "comment": "Rx",
    "other_names": [
        "Galafold"
    ],
    "classes": [
        "Pharmacologic Chaperones"
    ],
    "source": "https://reference.medscape.com/drug/galafold-migalastat-1000239",
    "pregnancy": {
        "common": [
            "Current study collects data on pregnant women with Fabry disease, either exposed or unexposed to GALAFOLD; healthcare providers are encouraged to register patients or obtain additional information by contacting the Pregnancy Coordinating Center at 1-888-239-0758; email fabrypregnancy@ubc.com, or visit ",
            "Available data are not sufficient to assess drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; in animal reproduction studies, no adverse developmental effects were observed"
        ],
        "specific": [
            {
                "type": "Infertility",
                "description": [
                    "Effects on fertility in humans not studied; transient and fully reversible infertility in male rats associated with treatment at systemic exposure (AUC) equivalent to human exposure at recommended dose; complete reversibility was seen at 4 weeks after termination of treatment; drug did not affect fertility in female rats"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Current study collects data on effects of GALAFOLD on lactation for women with Fabry disease and their neonates and infants up to 1 year of age who are exposed through breast milk; healthcare providers are encouraged to register patients or obtain additional information by contacting Pregnancy Coordinating Center at 1-888-239-0758, email fabrypregnancy@ubc.com, or visit ",
            "There are no human data available on the presence of the drug in human milk, the effects on breastfed infant, or on milk production; the drug is present in the milk of lactating rats; when a drug is present in animal milk, it is likely that the drug will be present in human milk; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on the breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None reported by the manufacturer"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "This porduct was approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "35"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "18"
        },
        {
            "name": "Urinary tract infection",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "12"
        },
        {
            "name": "Pyrexia",
            "percent": "12"
        },
        {
            "name": "Abdominal pain",
            "percent": "9"
        },
        {
            "name": "Back pain",
            "percent": "9"
        },
        {
            "name": "Cough",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Epistaxis",
            "percent": "9"
        }
    ]
}